There are increasingly more patients who have undergone transcatheter aortic valve replacement (TAVR) and require a non-cardiac intervention, or patients with other diseases who need surgery and are diagnosed with aortic stenosis. In addition, on many occasions, surgery must be performed as soon as possible (as in cases of cancer) or is an emergency procedure.<a href="https://solaci.org/en/2022/08/11/non-cardiac-surgery-after-tavr-is-safe/" title="Read more" >...</a>
On the last session from day 1 of SOLACI-SOCIME 2022 on structural pathology, Dr. Raj Makkar, an international expert on the subject, talked about transcatheter aortic valve replacement (TAVR) in pure aortic regurgitation (AR), which presents several implantation challenges, such as insufficient anchoring, embolization, residual regurgitation, ring rupture, etc. As opposed to patients with aortic<a href="https://solaci.org/en/2022/08/09/the-best-of-the-solaci-socime-2022-main-arena-structural-selected-topics-of-tavr/" title="Read more" >...</a>
TAVR has been reported beneficial in the treatment of high and intermediate risk patients but, initially, randomized clinical trials have shown vascular complication and pacemaker implantation rates higher than SAVR in low-risk patients. This will most certainly improve as operator experience and device development advance. This is a randomized 1:1 study including 458 patients receiving<a href="https://solaci.org/en/2022/06/09/tavr-more-information-supports-its-use/" title="Read more" >...</a>
Transcatheter aortic valve replacement (TAVR) is a therapeutical option for patients with symptomatic severe aortic stenosis. Current guidelines recommend TAVR in patients ≥75 years with intermediate risk. One of the most frequent complications of this procedure is moderate or greater aortic regurgitation (AR) after implantation. Consequently, new valves have been developed to try and reduce<a href="https://solaci.org/en/2022/06/03/new-generation-acurate-neo2/" title="Read more" >...</a>
Currently, the American and European guidelines recommend coronary angioplasty in patients with severe aortic stenosis with lesions >70% (Class IIa) who will undergo transcatheter aortic valve replacement (TAVR). However, the benefit of performing a revascularization in these patients is still uncertain. This prospective multicenter study included 2025 patients divided into two groups: complete revascularization (N = 1310)<a href="https://solaci.org/en/2022/05/24/europcr-2022-should-revascularization-be-performed-before-tavr-in-patients-with-stable-coronary-disease/" title="Read more" >...</a>
Once more, the Latin American Society of Interventional Cardiology (SOLACI) will attend two of the most important annual meetings in the field: the EuroPCR 2022 and the SCAI 2022 Scientific Sessions. The society will take part in with 2 challenging joint sessions to shar the Latin American reality in different areas of interest within the<a href="https://solaci.org/en/2022/05/16/solaci-present-at-the-main-interventional-cardiology-meetings-in-the-world/" title="Read more" >...</a>
DAPT-TAVR is a randomized trial that tested endoxaban in patients with no indication for anticoagulation who underwent successful transcatheter aortic valve replacement (TAVR) for symptomatic severe aortic stenosis. This study included 229 patients whose mean age was 80 years; 42% of them were male. Patients were randomized to either endoxaban 60 mg or 30 mg every 24 h or<a href="https://solaci.org/en/2022/04/13/acc-2022-adapt-tavr-endoxaban-is-not-superior-to-dapt-after-tavr/" title="Read more" >...</a>
Bicuspid aortic valve malformation is the most frequent cardiac malformation (about 1%), and a significant percentage of these cases generate severe aortic stenosis. As we know, transcatheter aortic valve replacement (TAVR) has been developed for tricuspid valves, which are studied in the most important randomized trials for high-, medium-, and low-risk patients. While current information<a href="https://solaci.org/en/2022/03/16/are-expandable-balloon-valves-an-option-for-the-bicuspid-valve-in-low-risk-patients/" title="Read more" >...</a>
In Europe and the US, aortic stenosis is the most frequent cause of valve intervention, both surgical and percutaneous, and, as we all know, TAVR has made great progress in this regard. However, this technique has an Achilles heel when it comes to self-expandable valves: definite pacemaker implantation rate is 3 to 4 times higher<a href="https://solaci.org/en/2022/03/11/is-cusp-overlapping-projection-the-new-self-expandable-valve-implantation-technique/" title="Read more" >...</a>
The Hydra CE has shown favorable one year efficacy for the new transcatheter aortic valve model, with large effective orifice and low transvalvular gradient associated to an acceptable complications rate. With this study, the Hydra will obtain the CE mark and go after FDA approval (just as all new devices). This study looked at safety<a href="https://solaci.org/en/2022/01/19/hydra-ce-new-models-for-tavr-development/" title="Read more" >...</a>